Representative Byron Donalds (Republican-Florida) recently bought shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on July 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in Zoetis stock on June 9th. The trade occurred in the Representative’s “MORAN WEALTH IRA” account.
Representative Byron Donalds also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of Cadence Design Systems (NASDAQ:CDNS) on 6/5/2026.
- Sold $1,001 – $15,000 in shares of Monolithic Power Systems (NASDAQ:MPWR) on 6/5/2026.
Zoetis Stock Down 0.6%
Shares of Zoetis stock traded down $0.47 during trading on Friday, hitting $76.44. 7,544,382 shares of the stock traded hands, compared to its average volume of 5,801,801. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The stock’s fifty day simple moving average is $77.33 and its 200 day simple moving average is $106.03. The firm has a market cap of $32.05 billion, a P/E ratio of 12.68, a price-to-earnings-growth ratio of 1.19 and a beta of 0.75. Zoetis Inc. has a 52-week low of $71.47 and a 52-week high of $160.48.
Zoetis Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.
Key Headlines Impacting Zoetis
Here are the key news stories impacting Zoetis this week:
- Positive Sentiment: Zoetis was named as title sponsor of PawsitiveIntelligence.ai, adding a small brand-visibility and industry-partnership angle. Pawsitive Holdings Announces Zoetis as Title Sponsor of PawsitiveIntelligence.ai
- Positive Sentiment: Some commentary argued Zoetis offers an attractive risk-reward setup, suggesting a more constructive long-term view despite recent volatility. Zoetis: An Attractive Risk-Reward Opportunity
- Neutral Sentiment: Zoetis’ upcoming second-quarter earnings report is getting attention, with analysts expecting modest growth and investors watching for updated guidance and commentary on diagnostics demand. Zoetis Earnings Preview: What to Expect
- Neutral Sentiment: Zoetis announced it will acquire VitalRADS, a veterinary teleradiology platform, which could support its diagnostics strategy and AI-enabled offerings. Zoetis Gains as VitalRADS Deal Boosts Diagnostics Narrative
- Negative Sentiment: Multiple law firms issued reminders and investor alerts tied to a securities class action against Zoetis, reinforcing concerns about litigation risk and possible reputational damage. Deadline Alert for CALX, AVAV, ZTS, LCID
- Negative Sentiment: Additional class-action notices specifically target Zoetis shareholders, underscoring that the lawsuit remains an active overhang for the stock. ZTS Shareholder Alert
- Negative Sentiment: The legal backdrop follows earlier reports alleging investor harm and reminding shareholders of the same July 27 deadline, keeping sentiment cautious. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Institutional Investors Weigh In On Zoetis
Institutional investors and hedge funds have recently modified their holdings of the company. Louisiana State Employees Retirement System acquired a new position in Zoetis in the first quarter valued at approximately $2,542,000. Nordea Investment Management AB grew its stake in shares of Zoetis by 79.2% during the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after purchasing an additional 2,179,578 shares during the period. Deutsche Bank AG increased its holdings in shares of Zoetis by 19.1% during the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock valued at $699,331,000 after purchasing an additional 891,921 shares in the last quarter. Seilern Investment Management Ltd increased its holdings in shares of Zoetis by 361.2% during the 4th quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock valued at $41,957,000 after purchasing an additional 261,155 shares in the last quarter. Finally, Pincus Capital Management LP acquired a new position in shares of Zoetis in the 4th quarter valued at $2,109,000. Institutional investors and hedge funds own 92.80% of the company’s stock.
Insider Buying and Selling
In other news, Director Michael B. Mccallister purchased 3,000 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the acquisition, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Paul Bisaro bought 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have bought 11,650 shares of company stock valued at $886,384. Corporate insiders own 0.22% of the company’s stock.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on ZTS shares. JPMorgan Chase & Co. dropped their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Morgan Stanley reiterated an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a research note on Friday, May 15th. Argus reissued a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Citigroup cut their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Finally, Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $120.83.
About Representative Donalds
Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida’s 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.
Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida’s 19th Congressional District. He declared candidacy for the 2026 election.
Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor’s degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.
Zoetis Company Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Further Reading
- Five stocks we like better than Zoetis
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
